Advertisement

Topics

Neos Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

19:00 EST 27 Feb 2017 | Globe Newswire

DALLAS and FORT WORTH, Texas, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer, will present a company overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET in Boston, MA. 

A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.

About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1

1Tussionex® is a registered trademark of the UCB Group of Companies.

Contacts:

Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com

Sarah McCabe
Vice President
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Neos Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...